Cargando…

Deep sequencing with longitudinal sampling of a VRC01-like-antibody response in a chronically infected individual

Detalles Bibliográficos
Autores principales:	Zhang, Z, Wu, X, Longo, N, Zhang, B, Zhu, J, NISC, C, Mullikin, JC, Wu, L, Nabel, GJ, Connors, M, Kwong, PD, Mascola, JR, Shapiro, L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441451/ http://dx.doi.org/10.1186/1742-4690-9-S2-O36

Ejemplares similares

Structure-guided modification and optimization of antibody VRC07
por: Kwon, Y, et al.
Publicado: (2012)

Characteristics of HIV-1 gp120 molecules that bind ancestor, intermediate and mature forms of VRC01-like antibodies
por: Joyce, M, et al.
Publicado: (2012)

Partial germline reversions can increase VRC07 potency and breadth
por: Rudicell, RS, et al.
Publicado: (2012)

P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)
por: Ledgerwood, JE, et al.
Publicado: (2009)

Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01
por: Lynch, RM, et al.
Publicado: (2012)

P13-01. Crystal structure and function of a monoclonal antibody against primate CD4 that blocks HIV/SIV infection
por: Pegu, A, et al.
Publicado: (2009)

Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials
por: Huang, Yunda, et al.
Publicado: (2018)

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
por: Seaton, Kelly E., et al.
Publicado: (2023)

Hyperglycosylated resurfaced stabilized GP120 core as an immunogen elicits antibodies targeted at the CD4-binding site
por: Dai, K, et al.
Publicado: (2012)

A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention
por: Kwon, Young D., et al.
Publicado: (2021)

Adjuvants influence the maturation of VRC01-like antibodies during immunization
por: Knudsen, Maria L., et al.
Publicado: (2022)

454 pyrosequencing and bioinformatics analysis of the lineage of the broad and potent gp41-directed antibody 10e8
por: Ofek, G, et al.
Publicado: (2012)

Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain
por: Kwon, Young D., et al.
Publicado: (2023)

Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound
por: Cale, Evan M., et al.
Publicado: (2020)

Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011)
por: Enama, Mary E., et al.
Publicado: (2014)

Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier
por: Bonsignori, Mattia, et al.
Publicado: (2018)

V5 region in the HIV-1 envelope glycoprotein determines viral sensitivity to the broadly neutralizing monoclonal antibody VRC01
por: Guo, D, et al.
Publicado: (2012)

Delayed vaginal SHIV infection in VRC01 and anti-α4β7 treated rhesus macaques
por: Calenda, Giulia, et al.
Publicado: (2019)

Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2019)

Transforming epitope-specific gp120 monomer-based probes into immunogens with N-linked glycan masking
por: Chuang, G, et al.
Publicado: (2012)

Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
por: Huang, Yunda, et al.
Publicado: (2021)

Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination
por: Mata-Fink, J, et al.
Publicado: (2012)

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2018)

Selection of Peptide Mimics of HIV-1 Epitope Recognized by Neutralizing Antibody VRC01
por: Chikaev, Anton N., et al.
Publicado: (2015)

Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features
por: Magaret, Craig A., et al.
Publicado: (2019)

Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization
por: Parks, K. Rachael, et al.
Publicado: (2019)

Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
por: Huang, Yunda, et al.
Publicado: (2021)

Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions
por: Caniels, Tom G., et al.
Publicado: (2023)

Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2
por: Liao, L, et al.
Publicado: (2012)

First-in-human immunoPET imaging of HIV-1 infection using (89)Zr-labeled VRC01 broadly neutralizing antibody
por: Beckford-Vera, Denis R., et al.
Publicado: (2022)

Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials
por: Mkhize, Nonhlanhla N., et al.
Publicado: (2023)

P09-05. Mechanism of HIV-1 resistance to a monoclonal antibody that effectively targets the site of CD4 attachment
por: Wu, X, et al.
Publicado: (2009)

Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies
por: Seydoux, Emilie, et al.
Publicado: (2021)

Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
por: Huang, Yunda, et al.
Publicado: (2023)

NMR spectroscopy of HIV-1 gp120 outer domain
por: Sastry, M, et al.
Publicado: (2012)

Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01
por: Cardozo-Ojeda, E. Fabian, et al.
Publicado: (2021)

A short segment in the HIV-1 gp120 V1/V2 region is a major determinant of neutralization resistance to PG9-like antibodies
por: Doria-Rose, NA, et al.
Publicado: (2012)

Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies
por: Otsuka, Yuka, et al.
Publicado: (2018)

A systematic analysis of the expression of the anti-HIV VRC01 antibody in Pichia pastoris through signal peptide optimization
por: Aw, Rochelle, et al.
Publicado: (2018)

Expressing anti-HIV VRC01 antibody using the murine IgG1 secretion signal in Pichia pastoris
por: Aw, Rochelle, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ehp66ihhga98ndm86f02hmd2v6